The US Food and Drug Administration on Monday approved the use of the experimental drug aducanumab for early phases of Alzheimer's disease -- despite an FDA advisory committee concluding last year ...

An advisory committee to the US Food and Drug Administration largely concluded in a meeting on Friday that there is not enough evidence to support the effectiveness of the experimental Alzheimer's ...

High-dose aducanumab, a human monoclonal antibody in development, significantly reduced clinical decline in people with early Alzheimer's disease in one randomized, placebo-controlled phase 3 study ...

The US Food and Drug Administration soon will consider whether to approve a new Alzheimer's drug for the first time in almost two decades. The US Food and Drug Administration soon will consider ...

For aducanumab, clinical trial inclusion criteria required specific scores on thinking and memory tests and that participants were ages 50 to 85. Researchers found 104 people, or 44%, would have met ...

Confirmatory trial’s completion is expected in an accelerated timeline of four years with patient screening to start in May Multiple strategies in place to enroll patients that are representative of ...

MINNEAPOLIS – Only a small percentage of older adults who are in the early stages of Alzheimer’s disease meet the eligibility criteria to receive new monoclonal antibody treatments, drugs that target ...

Aduhelm is the brand name of Aducanumab is one of the dementia medications that are approved or in trial, specifically in the treatment of Alzheimer disease. Even though in 2022, Biogen Inc.

If approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimer’s disease CAMBRIDGE, Mass. and TOKYO, July 08, 2020 (GLOBE NEWSWIRE) -- Biogen ...

A New York Times health reporter explains what clinical trials are, why they are important and how they can help inform us. Credit...Ricardo Tomás Supported by By Nina Agrawal Nina Agrawal is a health ...